Saturday, October 4
8:00 am – 10:00 am
Opening Session: The Spark: Igniting the Creative Fire That Lives Within Us All
Featuring Lyn Heward, Former president and COO, Cirque du Soleil
(please note earlier starting time)
Cirque du Soleil is widely recognized as one of the most innovative and creative companies in the world today. The person who developed and managed that creative fire for much of the company’s history is Lyn Heward. Beginning as an acrobatic scouting coordinator and creation studio director, Ms. Heward’s responsibilities evolved as Cirque du Soleil grew in scope. In 2000 she was named president and Chief Operating Officer of Cirque du Soleil’s Creative Content Division, a position she held until 2005. In the latter position, Ms. Heward was responsible for managing, guiding and channeling the incredible creative force of the company’s designers, performers, artisans and technicians into a product that was both breathtakingly original as well as commercially successful.
AABB is honored to have Ms. Heward as the opening session speaker in Montréal, where Cirque du Soleil is headquartered. In her presentation, she will go behind the scenes of the world-famous Cirque du Soleil to explore the nature of creativity and innovation. She will provide the audience with practical suggestions, as well as the inspiration to find and develop the creative spark that lives within us all. Making brilliant use of images and video from Cirque du Soleil’s groundbreaking shows, she will lead our attendees through a succession of stories, anecdotes and examples that are both instructional and motivational, and that touch a wide range of issues relevant to every organization, including risk-taking, leadership, teamwork and product development.
Sponsored by Olympus America Inc.
10:30 am – Noon
(9101-S) TTD I: Emerging Infectious Diseases
Director/Moderator: Susan Stramer, PhD
Faculty: Susan P. Montgomery, DVM, MPH; Azzedine Assal, MD; David Leiby, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Objectives:
- Summarize the CDC/blood center investigations of autochthonous cases of T. cruzi infection and current theories regarding risk.
- Learn about the various screening programs currently reported in the US.
- Describe the intervention processes to decrease the risk of transfusion transmission where Chikungunya has been epidemic.
- Compare the epidemiology and approaches for Chikungunya to those for dengue virus.
Event Description: This session will introduce and familiarize the audience with several transfusion transmissible and potentially transfusion transmissible agents considered to be emerging. Highlights of the program will include descriptions of the epidemiology of the agent, transmission routes, treatment of infected individuals, donor risk factors, description of major outbreaks, number of known transfusion transmitted cases, efficacy of methods for donor testing or removal and overall importance to patient safety.
Event Level: Intermediate to Advanced
(9102-S) Mouse Models in Transfusion Medicine: Platelets
Director/Moderator: Steven L. Spitalnik, MD
Faculty: Steven L. Spitalnik, MD; John W. Semple, PhD; Jim Zimring, MD, PhD; Alan H. Lazarus, PhD Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Learn the benefits of using mouse models to understand mechanisms underlying problems with platelet immunology and platelet transfusion.
- Understand the mechanisms involved in immunization to platelet autoantigens and alloantigens.
- Assess the use of mouse models to study the mechanisms underlying the therapeutic interventions for autoimmune thrombocytopenic purpura.
Event Description: Our understanding of the mechanisms underlying various phenomena in transfusion medicine remains incomplete. The use of animal models to study these issues can lead to new insights and therapeutic approaches. This workshop will discuss the use of mouse models to understand three topics related to the transfusion and immunology of platelets: immunization to platelet antigens, the pathophysiology autoimmune thrombocytopenic purpura (i.e. AITP), and the mechanisms underlying various immune-based therapies for treating AITP. The advantages of mouse models and the potential pitfalls in using such models will also be discussed.
Event Level: Intermediate to Advance
(9103-S) Growth Factors as Drugs I- Erythropoietins –ASH/AABB Joint Program
Director: Steven Sloan, MD, PhD
Moderator: Jeffrey McCullough, MD; Steven Sloan, MD, PhD
Faculty: John Adamson; Charles Bennett, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives:
- Evaluate the mechanism of action of erythropoietin and erythropoietin stimulating agents (ESAs).
- Assess the potential risks and benefits of ESAs.
- Determine the mechanism of action and potential clinical risks and benefits of newer drugs under development to stimulate erythropoiesis.
Event Description: Several drugs that are analogues of erythropoietin, the growth factor that stimulates red blood cell production, are used to treat anemia in some patient populations. While these erythropoietin analogues, also known as erythroid stimulating agents (ESAs), can be effective in decreasing the need for RBC transfusions in some patient populations, recent studies suggest that there may be thrombosis and cancer progression risks associated with these drugs. This session will describe the mechanism of action of erythropoietin, clinical benefits and risks of ESAs, the potential changes in clinical practices including RBC transfusion practices that may stem from recent clinical studies on ESAs, and the drugs currently under development.
Event Level: Intermediate to Advance
9104-TC- Relationship Testing I
Director/Moderator: Michael L. Baird, Ph.D.
Faculty: Michael L. Baird, Ph.D.; Mary K. Mount MT(ASCP); George Riley, Ph.D.
Intended Audience: Scientists, Technologists
Objectives:
- Discuss the changes in the 8th Edition of RT Standards and annual report summary.
- Describe the AABB Relationship Testing Laboratory assessment process.
- Present the recent AABB/CAP proficiency findings.
Event Description: This session covers administrative issues affecting Relationship Testing Laboratories. One part will include a discussion of the 8th Edition of Relationship Testing Standards that became effective January 1, 2008 as well as a summary of the most recent annual report of relationship testing. Another part will cover the assessment process and findings of any pattern of problems encountered. The last part will discuss findings from the AABB/CAP Relationship Testing Proficiency program.
Event Level: Basic
(9105-TC) Transfusion Safety Officers: U.S. and Canadian Perspectives
Director/Moderator: Martha Wieland, RN, BSN, HP(ASCP)
Faculty: Jeffrey Wagner, BSN, RN; Kim Maynard, RN, BSN, OCN; Ginette Labonte; Anne-Marie Martel
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Objectives:
· Define the role of a Transfusion Safety Officer in Canada.
Event Description: Transfusion Safety Officers are an emerging profession in the United States, and has a more established role in other countries. This program will examine the emerging role in the U.S. and compare and contrast it to similar roles in other countries. In doing this, the program will enhance the knowledge base of those involved in collecting, processing and administering transfusions as well as offering information on newly defined and emerging profession.
Event Level: Basic to Intermediate
(9106-TC) Molecular Immunohematology 101
Director/Moderator: Gregory A. Denomme, PhD
Faculty: Maryse St.-Louis, PhD; Jill Storry, PhD; Greg Denomme, PhD
Intended Audience: Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Review the concept of how DNA obtained from white cells can be used to infer a red cell phenotype.
- Provide the basic principles of the polymerase chain reaction using genomic DNA.
- Describe how DNA is manipulated to resolve alleles into blood group genotypes.
Event Description: Molecular biological techniques are finding important applications in immunohematology. As a result, many professionals require a basic understanding of molecular biology as it pertains to blood groups. However, front-line individuals may have little or no formal training, do not work with the techniques, but are expected to understand how DNA can be manipulated to predict red cell phenotypes. This education session will provide the fundamentals of the polymerase chain reaction (PCR), using genomic DNA harvested from white cells, and the manipulation of PCR products to translate DNA tests into predicted blood group phenotypes. This session is designed for individuals who wish to start with basic principles and simple language in the technique of genomic DNA amplification and blood group genotyping.
Event Level: Basic to Intermediate
(9107-TC) Interface Between the Coagulation Laboratory and Cardiovascular Surgery, What's What? SABM/AABB Joint Program
Director/Moderator: Aryeh Shander, MD, FCCM, FCCP
Faculty: Darrell Triulzi, MD; Arthur Bracey, MD; Linda Shore-Lesserson, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Describe the limitations of testing of platelet function and number.
- Recognize the caveats in platelet administration: number, function and effect.
- Evaluate the indications and therapeutic limitations of the value of plasma.
- Determine the limitations of clinical tests for hemostatic pharmaceutical agents.
Event Description: The diagnosis and treatment of bleeding secondary to coagulation abnormalities continues to plague clinicians managing cardiac surgery patients. Cardiopulmonary bypass results in derangement of the coagulation system. Another issue is the newer, more potent anticlotting agents used liberally with the aging population to prevent arterial thrombotic events. Diagnosis of coagulation disorders in these patients is fraught with problems of sensitivity and specificity of available tests. Correlation of test results such as elevated INR or low platelet count with predictable clinical bleeding scenarios requires assumptions that often prove to be wrong. Blood products used to "treat" these conditions often do not reverse noted coagulation abnormalities. These problems continue without resolution or with little attempt to educate and clarify current understandings of available tests and "true" activity of available therapeutic interventions. Since few products can reverse these agents reliably, inappropriate testing and increased use of blood products adds to this problem.
Event Level: Intermediate
(9108-TC-CT) Essentials and Advances in Cell Culture
Director: N. Rebecca Haley, MD, MT(ASCP)SBB
Faculty: Scott Pruitt, MD, PhD; Bruce Levine, PhD; Ivan Borrello, MD
Intended Audience: Physicians, Scientists, Technologists
Objectives:
- Describe two novel cell manipulation techniques being used in cancer trials.
- List three essential tests that the cell preparations must pass before being given to patients.
- Describe two novel approaches to cell manipulation and/or priming to transform them into treatments.
- Evaluate whether the methods described could be reproduced in your laboratory.
Event Description: This session will feature three speakers who are leaders in the field of novel cell preparations under IND investigations in the fight against cancer. They represent important basic science observations where the investigators had the foresight and perseverance to take them to clinical trials. Each speaker will discuss the basic science observation that they worked from and trace the steps that were necessary to qualify the ideas and methods for human use. Novel methods to be discussed are RNA-charging of dendritic cells with tumor antigen to hopefully stimulate the patient's immune system with the antigens hyper-expressed, in-vitro exposure of immune cells to antigen for immune priming and the large-volume expansion of targeted immune cells on microcarriers.
Event Level: Intermediate to Advanced
(9109-QE) Use of Laboratory Accreditation Observations and Proficiency Tests Data for Continuous Performance Improvement
Director: Janis Nossaman, MT(ASCP)SBB
Faculty: Beverly Padget, MT, ART(CSMLS); Elizabeth McBride, BSc(MLS)MT(CSMLS); Judith Hannon, MD(FRCPC)
Moderator: Merilyn Wiler, MT(ASCP)SBB, MAEd
Intended Audience: Technologists, Managers/Supervisors
Objectives:
· Describe the operation of an accreditation and proficiency testing program
· Examine the performance level of transfusion services, including common inspection observations and proficiency testing performance issues.
· Identify how accreditation and proficiency testing data can be used for staff development and process improvement.
Event Description: Would you like more value from your laboratory’s accreditation and proficiency testing outcomes? This program will present models for ways to improve utilization of the data to guide your CI program. An overview of a Canadian Transfusion Service Accreditation program and its partner proficiency testing program will include an analysis of observations, errors and investigations with the outcome of identifying performance improvement measures.
Event Level: Intermediate
(9110-RC) Hiring, Retaining, Motivating and Developing Collection Staff
Director/Moderator: Andrea Hatle, BS
Faculty: James Tueller, SPHR; Vicki Finson, MT(ASCP)SBB; Lesli Asay
Intended Audience: Managers/Supervisors, CEOs/CFOs
Objectives:
- Identify successful ways to attract and hire the right personnel for collections.
- Explore motivating and creative ways to train collection staff and encourage growth and retention.
- Discover successful ways to retain and reduce turnover in collections via motivation and staff development.
Event Description: Finding and keepting the "perfect" individual who will stay on board long term and remain motivated in the collections department is a manager's dream! Learn how to continue through the processes of hiring and developing staff in a motivating manner through the presentations of a human resource director, donor care manager, and executive director with proven results.
Event Level: Intermediate
(9111-RC) Internet Marketing is Nothing to LOL@ -- ADRP/AABB Joint Program
Director: Joyce Kleist
Moderator: John Hagins
Faculty: Gene Young, BS; Shankar Goudar, BSE, MS, MBA
Intended Audience: Managers/Supervisors
Objectives:
- Differentiate between viral and social marketing and uses for both in the blood center environment.
- Discover how email "chat" can be a great communication tool to interact with donors.
- Learn the basics of text messaging donors and the benefit of implementing this method of contacting your donors.
- Understand "blogosphere” basics.
Event Description: Effective communication with donors continues to be a challenge for blood centers. Understanding the technologies that are available may be the answer to our quest of communicating more effectively with our donor base. Individuals attending this session will learn about a variety of techniques available to communicate with donors and potential donors through the use of the internet.
Event Level: Basic to Intermediate
(9112-LMT) Coding and Reimbursement
Director/Moderator: William B. Lockwood, PhD, MD
Faculty: William B. Lockwood, PhD, MD; John Carlsen, MHA; Suzanne Butch, MA, MT(ASCP)SBB, CQA(ASQ)
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives:
- Describe recent changes to properly bill transfusion medicine services and blood/tissue products.
- Learn current Medicare outpatient billing requirements using case-based scenarios with audience participation.
- Describe the differences in billing transfusion medicine services for Medicare outpatient and inpatient beneficiaries.
Event Description: The program will present an update to billing the Medicare outpatient for transfusion medicine services, blood components and tissue. Case-studies of common as well as unique scenarios will be used to stimulate audience participation in discussing their understanding of the current billing requirements. A faculty panel will be utilized in a question and answer session to assist the program participant in proper billing practices of transfusion medicine.
Event Level: Basic to Intermediate
(9113-CO) Developing an Entrepreneurial Orientation in Established Organizations
Director/Moderator: Stephen Eason, MBA, CFRE
Faculty: Chuck Bamford, Ph.D.
Intended Audience: Managers/Supervisors, CEOs/CFOs
Objectives:
- Learn the five important questions every organization must answer
- Describe the 8 things that must be present for innovation success
Event Description: What do 3M, Whirlpool and WD-40 have in common? They accomplished one of the biggest tasks faced by all established companies. That is how to generate new sources of income that take advantage of resources and capabilities that already lie within the organization. Every company that you can think of started as an entrepreneurial organization and grew because it was providing something of real value to their customers. Losing that innovative spark and the ability to continually re-invent your company does have to be inevitable.
Event Level: Intermediate
Noon – 2:00 pm
(9114-S) NBF Grant Recipient Luncheon (ticket required)
Award Recipients: Jose Cancelas Perez, MD, PhD; Christine Cserti-Gazdewich, HBSc, MD, FRCPC; Spero Cataland, MD
Director/Moderator: Connie Westhoff, PhD, MT(ASCP)SBB
Intended Audience: Physicians, Scientists, Technologists
Objectives:
- Discover how the NBF Scientific Research Grants Program has helped early-career investigators develop transfusion medicine research.
- Understand and appreciate how NBF-funded exploratory research activities have driven developments that improve patient and donor care.
- Learn cutting-edge discoveries that will shape transfusion medicine in the future.
Event Description: This program showcases the research activities of three early-career transfusion medicine investigators who have leverged NBF seed grant funding into a high- profile career in transfusion medicine research. Enjoy a delicious lunch while these three scientists discuss their latest research with a focus on the role their findings will play in driving the future of transfusion medicine. Time for questions and informal discussion is provided.
Event Level: Intermediate to Advanced
This luncheon is complimentary to all attendees registered for the full meeting or Saturday, Oct. 4 only. A ticket is required to attend and seating is limited. Please check the appropriate box in Section 7 on the registration form.
(9115-TC) Transfusion Practices and Therapeutic Apheresis (Formerly Nursing Luncheon)
Director: Martha Wieland, RN, BSN, HP(ASCP)
Moderator: Kim Palmer, BS, RN
Faculty: Tina Chanez, MBA, MT(ASCP), CQA(ASQ)CQM; Mary Heintz, MT(ASCP)SBB; Nancy Kelting, MT(ASCP)
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Identify three criteria involved in the diagnosis of TRALI.
- List one modality used in the treatment of TRALI.
· Describe an example of donor follow-up used when a documented case of TRALI is determined.
Event Description: A case study presentation of a patient who developed TRALI following a transfusion will be followed by a discussion of the diagnosis and treatment of TRALI. The session will also discuss donor testing and follow-up. This program will be interactive and offer an opportunity for networking and collegial discussion.
Event Level: Basic to Intermediate
This luncheon is complimentary to all attendees registered for the full meeting or Saturday, Oct. 4 only. A ticket is required to attend and seating is limited. Please check the appropriate box in Section 7 on the registration form.
2:00 pm – 3:30 pm
(9117-S) Growth Factor as Drugs II- Thrombopoietins – ASH/AABB Joint Program
Director: Steven Sloan, MD, PhD
Moderators: Jeffrey McCullough, MD; Steven Sloan, MD, PhD
Faculty: David Kuter, MD, DPhil; James Bussel, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives:
- Assess the mechanism of action of thrombopoietin.
- Determine the rationales for developing thrombopoietin agents for therapeutic purposes.
- Describe the risks and benefits of thrombopoietin agents found in clinical trials.
Event Description: Thrombopoietin (TPO) is the principal growth factor that stimulates platelet production. Initial attempts to develop TPO agents caused unacceptable adverse events. Since then, new agents have been developed to minimize the risk of side effects associated with the original thrombopoietin analogues, and one will soon be available for clinical use in the US. This session will describe the mechanism of action of thrombopoietin, benefits and risks of TPO agents found in early and more recent clinical trials, and the potential clinical uses of these agents and impact on platelet transfusion practices.
Event Level: Intermediate to Advanced
(9118-S) Novel Mechanisms of Action of IVIg in Autoimmune and Inflammatory Diseases
Director: Real Lemieux, PhD
Moderator: Renee Bazin, PhD
Faculty: Real Lemieux, PhD; Srini Kaveri, PhD; Marc E. Weksler, MD
Intended Audience: Physicians, Scientists, Technologists
Objectives:
- Assess the high diversity of human autoantigens recognized by IVIg.
- Appraise the ability of IVIg to modify the populations of activated T lymphocytes.
- Cite the potential mechanisms of action of IVIg in Alzheimer's disease.
Event Description: Much of the recent research done on the immunomodulatory effects of IVIg infusion has been focused on its ability to inhibit phagocytosis of opsonized platelets through modulation of FcgammaRs activity. However it is increasingly clear that many of the immunomodulatory effects of IVIg may be dependent on the ability of IVIg to bind directly to a wide variety of human structures. Thus the autoantibodies present in IVIg could interfere directly or indirectly with the pathologic process. The speakers will discuss the diversity and origin of autoantibodies present in IVIg and describe two recently reported situations where the autoantibodies could play significant roles: modulation of activated T lymphocytes and clinical use in Alzheimer's disease patients.
Event Level: Intermediate to Advanced
(9119-S-CT) New Aspects of Stem Cell Mobilization and Homing
Director: Anna Janowska-Wieczorek, MD, PhD
Moderator: Anna Janowska-Wieczorek, MD, PhD; Mariusz Ratajczak, MD, PhD
Faculty: Anna Janowska-Wieczorek, MD, PhD; Mariusz Ratajczak, MD, PhD; Magdalena Kucia, PhD Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Objectives:
- Determine the novel role of complement in hematopoietic stem cell mobilization and homing.
- Understand the part played by matrix metalloproteinases in stem cell mobilization and homing.
Event Description: This session will provide insights into new findings on the mechanisms of hematopoietic stem cell mobilization and homing after transplantation and on the discovery of very small embryonic-like (VSEL) stem cells in mobilized peripheral blood. The speakers will explain why it’s believed the complement (C) cascade and innate immunity are important modulators of trafficking of hematopoietic stem/progenitor cells (HSPC). The content will show that C becomes activated in bone marrow during G-CSF-induced mobilization by the classical Ig-dependent pathway, and C3 cleavage fragments increase the responsiveness of HSPC to stromal-derived factor-1(SDF-1). We will also describe the role of matrix-degrading enzymes in stem cell trafficking. One presentation will focus on characterization of a population of VSEL stem cells discovered in adult bone marrow by the Louisville research team; these VSEL cells enter the circulation during G-CSF-induced or stress-related mobilization and could play a role in organ/tissue regeneration.
Event Level: Advanced
(9122-TC) Something New: Chagas Notification Issues
Director/Moderator: Debra Kessler, RN, MS
Faculty: Louis M. Katz, MD; Ross Herron, MD; Susan Stramer, PhD
Intended Audience: Physicians, Nurses, Managers/Supervisors
Objectives:
- Know signs and symptoms of early infection (recipients) vs chronic infection (donors) and treatment for each so that counseling and referral are appropriate.
- Review issues involved in routine donor and recipient counseling.
- Explore aspects of unusual testing and counseling efforts in the face of absence of risk.
Event Description: Testing for Trypanosoma Cruzi, the cause of Chagas Disease, has been available for more than one year. As positive donors and recipients are being identified, counseling interventions are evolving with experience. This session is dedicated to the review of current practices in counseling donors who test positive for t. Cruzi. Though blood centers and transfusion services will not treat the infected donor/recipient, medical issues involved in Chagas Disease will be discussed to give counseling personnel an understanding of the disease and treatment. Routine counseling experiences will be reviewed as well as investigation of unusual testing and counseling efforts in the face of no identified risk of infection.
Event Level: Intermediate to Advanced
(9123-TC) FFP: Uses, Misuses and Current Studies
Director/Moderator: Heather Hume, MD, FRCPC
Faculty: Simon Stanworth, MA, MRCP (Paeds, U.K.), D.Phil., MRCPath; Alan Tinmouth, MD, FRCPC; Marie Steiner, MD, MS
Intended Audience: Physicians, Scientists, Technologists, Nurses, Perfusionists
Objectives:
- Review the current evidence supporting or not supporting the use of frozen plasma/fresh frozen plasma (FP/FFP) and also the utilization studies of FP/FFP.
- Describe on-going studies examining FP/FFP use including studies evaluating the use of FP/FFP for emergency coumadin reversal in the presence of serious bleeding.
Event Description: In this session, transfusion medicine experts with extensive experience in evaluating the use — and misuse — of FP/FFP will review the current evidence supporting the use of this blood component and discuss on-going studies involving the use of FP/FFP including its use, versus the use of prothrombin complex concentrates, for coumadin reversal in patients with intracranial hemorrhage. This workshop will provide a useful background to a related workshop examining the role of plasma in the resuscitation of patients with massive bleeding.
Event Level: Intermediate to Advanced
(9125-TC-CT) Regenerative Medicine: New Developments
Director/Moderator: James Yoo, MD, PhD
Faculty: Timothy Bertram, PhD; Mark Van Dyke, PhD; Stephen Badylak, DVM, PhD, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs, Perfusionists
Objectives:
- Discuss scaffold based therapies for clinical applications.
- Describe the commercialization of regenerative medicine products.
- Recognize innovative technologies that are designed to accelerate translation of regenerative therapies.
Event Description: This session will provide detailed insight into the rapidly evolving area of regenerative medicine therapies. A special attention will be placed on the development of scaffold based therapies for various applications. The session will also include the steps involved in commercializing regenerative medicine products. While some of the regenerative therapies have successfully translated into patients, a large number of investigations still remain experimental due to the technological challenges. Several enabling technologies that address the present challenges will be discussed.
Event Level: Intermediate
(9126-QE) Tracking and Trending: Are You Really In Control?
Director/Moderator: Monica Bradley, BS, CQA (ASQ)
Moderator: Monica Bradley, BS, CQA (ASQ)
Faculty: Lisa Walters, PhD, MBA, MT(ASCP)SBB, QSA(A2LA); Melanie Champion, MBA, MT(ASCP)SBB,HP; Sharon O’Callaghan, MT(ASCP)
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives:
- Describe components of tracking and trending programs for both donor centers and transfusion services.
- Outline types of indicators or quality activities that can be evaluated for trends.
- Apply methods to gather and analyze data and to establish thresholds for data.
- Review FDA's perspective on tracking and trending.
Event Description: Determining what to track, what to trend, how to trend/track, and when to take action can seem like insurmountable tasks. Add to this the question of "Are you really in CONTROL?" and fear is struck in all of us. In this session, speakers representing blood donor centers, transfusion services an